Newsletter - April 28, 2016
Use of FDA’s Expedited Approval Programs: How Fast is Too Fast
This week FDA’s Advisory Committee (Ad Com) voted to reject Sarepta Therapeutics’ new drug for Duchenne Muscular Dystrophy (DMD) despite emotional pleas from patient groups and physicians in support of the drug. DMD treatments are eligible for most of FDA’s expedited approval pathways such as orphan drug designation, fast track designation, priority review status, and breakthrough designation. Read More..
Does Passionate CEO and Illegal Clinical Research Lead to Good Science?
This week, the Seattle-based gene therapy company, BioViva, made a bold claim to have invented the world’s first “successful” gene therapy for aging. The evidence for efficacy and safety of its product was generated in a manner that raises serious concerns of ethics, good scientific practices, and regulatory oversight. What is clearly a publicity stunt may be considered illegal research by most regulatory agencies in the World. Read More..
Use of FDA’s Expedited Approval Programs: How Fast is Too Fast
This week FDA’s Advisory Committee (Ad Com) voted to reject Sarepta Therapeutics’ new drug for Duchenne Muscular Dystrophy (DMD) despite emotional pleas from patient groups and physicians in support of the drug. DMD treatments are eligible for most of FDA’s expedited approval pathways such as orphan drug designation, fast track designation, priority review status, and breakthrough designation. Read More..
Does Passionate CEO and Illegal Clinical Research Lead to Good Science?
This week, the Seattle-based gene therapy company, BioViva, made a bold claim to have invented the world’s first “successful” gene therapy for aging. The evidence for efficacy and safety of its product was generated in a manner that raises serious concerns of ethics, good scientific practices, and regulatory oversight. What is clearly a publicity stunt may be considered illegal research by most regulatory agencies in the World. Read More..